Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Posterior Vitreous Detachment, Diabetic Retinopathy
Interventions: annular array ultrasound exam; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions: MHU650; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more

Conditions: Diabetic Retinopathy
Interventions: Non-mydriatic color fundus photography with the RetinaVue camera, Referral for dilated eye exam with an eye care professional; Diagnostic Test
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions: Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension, Retinal Disorder, Cognitive Impairment
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Boston, Massachusetts • Reno, Nevada + 4 more

Conditions: Diabetic Retinopathy
Interventions: Anecortave Acetate Sterile Suspension (15 mg); Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Macular Edema
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 48
States / cities: La Jolla, California • Redlands, California • Santa Maria, California + 44 more

Conditions: Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions: Not listed
Lead sponsor: Optos, PLC; Industry
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas

Conditions: Retinal Vein Occlusion (RVO), Macular Edema
Interventions: Ozurdex implant; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
Interventions: Paxos Checkup Study Mobile Medical Application; Other
Lead sponsor: Digisight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Mountain View, California • Fort Myers, Florida + 9 more

Conditions: Retinal Diseases, Telangiectasis
Interventions: ranibizumab 2.0mg; Drug
Lead sponsor: Eye Center of Northern Colorado, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Diabetic Retinopathy
Interventions: Blood draw; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions: Latanoprostene bunod 0.024% QD, Timolol maleate 0.5% BID; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Macular Edema, Cystoid, Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cognitive Impairment, Progressive, Cerebral Small Vessel Diseases
Interventions: High-Speed Circuit Resistance Training, Lecture on Diet, Exercise and Cognition; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 65 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Coral Gables, Florida

Conditions: Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
Interventions: CD34+ bone marrow stem cells intravitreal; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetic Retinopathy
Interventions: Laser Photocoagulation, Bevacizumab; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more

Conditions: Diabetic Retinopathy
Interventions: Peribulbar Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions: Microscope integrated optical coherence tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 4 Weeks and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Macular Edema
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Diabetic Retinopathy
Interventions: ruboxistaurin, placebo; Drug
Lead sponsor: Chromaderm, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Macular Degeneration, Retinal Vein Occlusion
Interventions: Triamcinolone Acetonide (TAC-PF); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Annular Array Ultrasound in Ophthalmology

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

RetinaVue Diabetic Screening

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

DETECT and Retinal Outcomes in Hypertension

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

Biomarker of Diabetic Retinopathy

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

Vascular Endothelial Growth Factor (VEGF) in Uveitis

Circuit Training and Retina

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

Intraoperative OCT Guidance of Intraocular Surgery II

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders